

Seviteronel

Catalog No: tcsc3139



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

1610537-15-9

Formula:

$C_{18}H_{17}F_4N_3O_3$

Pathway:

Metabolic Enzyme/Protease

Target:

Cytochrome P450

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 50 mg/mL (125.21 mM)

Alternative Names:

VT-464

Observed Molecular Weight:

399.34


Product Description

Seviteronel (VT-464) is a potent CYP17 lyase inhibitor (h-Lyase IC_{50} = 69 nM) that demonstrated both exceptional in vitro lyase/hydroxylase selectivity (~10-fold) and oral activity in a hamster model of androgen biosynthesis inhibition.

IC50 & Target: IC50: 69 nM(h-CYP17 Lyase)^[1].

In Vitro: Seviteronel (VT-464), a non-steroidal small molecule inhibits androgen production without mineralocorticoid excess or cortisol depletion by selective inhibition of CYP17 17,20-lyase. We determined the impact of Seviteronel (VT-464) on tumor growth of a mCRPC xenograft, MDA-PCa-133, in vivo, and on androgen signaling in C4-2B prostate cancer cells in vitro^[2].

In Vivo: The MDA-PCa-133 xenograft is derived from a clinical CRPC bone metastasis. Subcutaneous MDA-PCa-133 tumor expresses PSA, full-length androgen receptor (AR) and AR-V7 isoform. We determined the effect of Seviteronel (VT-464) and AA on MDA-PCa-133 growing in tumor-bearing castrated male mice: randomization into three groups; oral treatment with vehicle only, VT-464, (100 mg/kg bid), or AA (100 mg/kg bid) for 25 days. Both Seviteronel (VT-464) and AA reduced tumor volume (>two fold compared to vehicle; p



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!